Susquehanna International Group’s CAMP4 Therapeutics CAMP Stock Holding History

Susquehanna International Group’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Buy	+336,047	New	+$1.6M	﹤0.01%	6914

Other funds holding CAMP

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's CAMP Position: Q1 2026 in Review

Susquehanna International Group opened a new position in CAMP4 Therapeutics (CAMP) in Q1 2026: 336,047 shares worth $1.48M. The stake represents ﹤0.01% of the portfolio and ranks #6914 among its holdings.

46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

Susquehanna International Group held 336,047 shares of CAMP4 Therapeutics worth $1.48M as of Q1 2026.
CAMP4 Therapeutics was a new Susquehanna International Group position in Q1 2026.
CAMP4 Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6914 holding.
46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.